An observational study in Intensive Care (ICU), Critical Illness and Alcohol Misuse, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Medical University of Vienna · Observational
The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is:
Do elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.
1,780 studies on the registry are indexed under Critical Illness; 442 are open to participants now.
This study's planned enrollment of 800 is above the median of 140 across 814 observational studies indexed under Critical Illness.
Browse Critical Illness studies →Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.
Compared within Critical Illness, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Study participants will be selected from adult patients admitted to the Department of Emergency Medicine who are subsequently transferred to an in-house intensive care unit (ICU). The study population consists of critically ill non-traumatic ICU patients receiving routine emergency and intensive care treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Carbohydrate-deficient transferrin (CDT) measurement is performed at ICU admission as an objective biomarker of sustained hazardous alcohol consumption during the previous 1-3 weeks. CDT values are obtained from routinely collected blood samples in adult non-traumatic ICU patients admitted via the emergency department. The study is purely observational and does not involve administration of a therapeutic intervention or changes to standard clinical care. CDT levels are analyzed in relation to outcomes including 30-day mortality, ICU length of stay, mechanical ventilation, delirium, renal replacement therapy, and ICU readmission.
The primary outcome of the study is 30-day all-cause mortality in ICU patients.
30-day all-cause mortality is defined as death from any cause occurring within 30 days after ICU admission. Mortality status will be assessed using patient medical records and, if unavailable, through the Austrian "Zentrales Personenstandsregister" (Central Civil Status Register), which documents registered deaths. Outcomes will be compared between patients with elevated and non-elevated carbohydrate-deficient transferrin (CDT) levels measured at ICU admission.
Time frame: From ICU admission to 30 days after ICU admission
In-hospital mortality
Death from any cause occurring during the index hospital stay.
Time frame: From hospital admission to hospital discharge evaluated 6 Months after study inclusion
ICU length of stay
Duration of stay in the intensive care unit, measured in days from ICU admission to ICU discharge.
Time frame: From ICU admission to ICU discharge evaluated 6 Months after study inclusion
Duration of mechanical ventilation
Total duration of mechanical ventilation during the ICU stay, measured in hours or days.
Time frame: From initiation of mechanical ventilation to successful discontinuation during ICU stay evaluated 6 Months after study inclusion
Illness severity score
Severity of illness assessed using TISS(-A), with a higher score signaling higher severity
Time frame: Evaluated from the documentation 6 Months after study inclusion
Illness severity score
Severity of illness assessed using APACHE II , with a higher score signaling higher severity
Time frame: Evaluated from the documentation 6 Months after study inclusion
Illness severity score
Severity of illness assessed using SAPS II, with a higher score signaling higher severity
Time frame: Evaluated from the documentation 6 Months after study inclusion
Illness severity score
Severity of illness assessed using SOFA scores, with a higher score signaling higher severity
Time frame: Evaluated from the documentation 6 Months after study inclusion
Plan to share: Undecided — De-identified individual participant data (IPD) underlying the reported study results, including demographic characteristics, laboratory values, CDT measurements, clinical parameters, and outcome data, may be shared upon reasonable request after publication of the primary results. Data containing directly identifiable personal information will not be shared in order to protect participant privacy and comply with applicable data protection regulations. Requests for access will be evaluated by the study investigators and institutional authorities.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.
Of 439 non-industry observational studies under Critical Illness, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 23 months is close to that.
Counting every sponsor, half of 442 studies reached it within 23 months; a quarter within 12 and three quarters within 46.
Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →